AdvaMed Names New EVP of Technology and Regulatory Affairs

Why It Matters

Torres’s deep FDA expertise strengthens AdvaMed’s ability to influence policy, accelerating market access for innovators and protecting patient safety across the medtech sector.

Key Takeaways

• Melissa Torres brings 20+ years FDA experience.
• Succeeds Janet Trunzo after three decades at AdvaMed.
• Will lead regulatory strategy for U.S. and global markets.
• Has shaped IMDRF and MDSAP international initiatives.
• Enhances AdvaMed’s advocacy for efficient device approvals.

Pulse Analysis

AdvaMed’s leadership transition underscores the growing complexity of medical‑device regulation. As the industry grapples with evolving safety standards, data‑driven approvals, and cross‑border compliance, the association’s technology and regulatory affairs division serves as a critical conduit between innovators and agencies such as the FDA and HHS. By appointing a seasoned regulator, AdvaMed signals its commitment to maintaining a proactive stance on policy development, ensuring that member companies can navigate the increasingly intricate approval landscape with confidence.

Torres’s résumé reflects a rare blend of technical acumen and diplomatic skill. At the FDA’s Center for Devices and Radiological Health, she directed international affairs, steering collaborations within the International Medical Device Regulators Forum and the Medical Device Single Audit Program. Her involvement in drafting the Quality Management System Regulation and negotiating Medical Device User Fee Amendments demonstrates a track record of shaping rules that balance rigorous safety oversight with industry feasibility. This background equips her to champion harmonized standards that reduce redundancy for manufacturers seeking global market entry.

For medtech firms, Torres’s appointment could translate into faster, more predictable pathways to market. Her experience with both pre‑market and post‑market frameworks positions her to advocate for streamlined review processes, clearer guidance on emerging technologies, and stronger alignment between U.S. and international regulators. As the sector accelerates toward digital health, AI‑driven diagnostics, and personalized devices, AdvaMed’s enhanced regulatory voice may become a decisive factor in shaping the next wave of innovation while safeguarding patient outcomes.